Morgan Stanley Initiates Coverage On ProKidney With Equal-Weight Rating, Announces Price Target of $13
Morgan Stanley Initiates Coverage On ProKidney With Equal-Weight Rating, Announces Price Target of $13
摩根士丹利以同等權重評級啓動對ProKidney的保險，宣佈目標股價爲13美元
Morgan Stanley analyst Vikram Purohit initiates coverage on ProKidney (NASDAQ:PROK) with a Equal-Weight rating and announces Price Target of $13.
摩根士丹利分析師維克拉姆·普羅希特以同等權重評級啓動了對ProKidney（納斯達克股票代碼：PROK）的報道，並宣佈目標股價爲13美元。
譯文內容由第三人軟體翻譯。
以上內容僅用作資訊或教育之目的，不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。